Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
Review: Opioid substitution therapy access with HIV care improves antiretroviral treatment outcomes for people who inject drugs
From starting treatment, to sticking with it, to suppressing virus, from the United States to Ukraine, services that support dual needs of people who inject drugs […]
Declaration flags resistance to antibiotics, including for TB treatment, as “greatest and most urgent global risk” Emphasizing imperatives to strengthen local health surveillance and service capacities […]
From a human-scented mosquito trap to rapid diagnostics, USAID funds research and development against Zika
Agency picks 21 of 900 ideas from around the world A research center in Tanzania will develop inexpensive sandals treated to ward off mosquito bites. Investigators […]
Launch of 2016 replenishment of funds to fight three diseases comes close to goal, exceeds 2013 donations The $12.9 billion in donations to the Global Fund to […]